US Patent

US11162500 — Stable liquid formulation of AMG 416 (etelcalcetide)

Formulation · Assigned to Amgen Inc · Expires 2034-06-27 · 8y remaining

Vulnerability score 42/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects a stable liquid formulation of the peptide agonist etelcalcetide, also known as AMG 416.

USPTO Abstract

A liquid formulation comprising a peptide agonist of the calcium sensing receptor and method of preparing and using the formulation are provided.

Drugs covered by this patent

Parsabiv (ETELCALCETIDE) · Kai Pharms Inc

Patent Metadata

Patent number: US11162500
Jurisdiction: US
Classification: Formulation
Expires: 2034-06-27
Drug substance claim: No
Drug product claim: Yes
Assignee: Amgen Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.